Abstract
Postprandial lipemia (PPL) refers to a dynamic sequence of plasma lipid/lipoprotein changes induced by ingestion of food. PPL results from absorption of digested dietary lipids which form chylomicrons (CM) and increased hepatic production of VLDL, stimulated by increased delivery of fats to the liver. In general, PPL occurs over 4-6 h in normal individuals, depending on the amount and type of fats consumed. The complexity of PPL changes is compounded by ingestion of food before the previous meal is fully processed. PPL testing is done to determine the impact of (a) exogenous factors such as the amount and type of food consumed, and (b) endogenous factors such as the metabolic/genetic status of the subjects, on PPL. To study PPL appropriately, different methods are used to suit the study goal. This paper provides an overview of the methodological aspects of PPL testing. It deals with markers of postprandial lipoproteins, testing conditions and protocols and interpretation of postprandial data. The influence of the meal itself will not be discussed as it is the subject of another paper in this series.
Keywords: Lipoprotein remnants, markers of postprandial lipoproteins, methodology, postprandial lipemia, triglyceride-rich lipoproteins, triglycerides, chylomicrons, VLDL, apoprotein, retinyl palmitate
Current Vascular Pharmacology
Title: Methods to Study Postprandial Lipemia
Volume: 9 Issue: 3
Author(s): Teik Chye Ooi and Borge G. Nordestgaard
Affiliation:
Keywords: Lipoprotein remnants, markers of postprandial lipoproteins, methodology, postprandial lipemia, triglyceride-rich lipoproteins, triglycerides, chylomicrons, VLDL, apoprotein, retinyl palmitate
Abstract: Postprandial lipemia (PPL) refers to a dynamic sequence of plasma lipid/lipoprotein changes induced by ingestion of food. PPL results from absorption of digested dietary lipids which form chylomicrons (CM) and increased hepatic production of VLDL, stimulated by increased delivery of fats to the liver. In general, PPL occurs over 4-6 h in normal individuals, depending on the amount and type of fats consumed. The complexity of PPL changes is compounded by ingestion of food before the previous meal is fully processed. PPL testing is done to determine the impact of (a) exogenous factors such as the amount and type of food consumed, and (b) endogenous factors such as the metabolic/genetic status of the subjects, on PPL. To study PPL appropriately, different methods are used to suit the study goal. This paper provides an overview of the methodological aspects of PPL testing. It deals with markers of postprandial lipoproteins, testing conditions and protocols and interpretation of postprandial data. The influence of the meal itself will not be discussed as it is the subject of another paper in this series.
Export Options
About this article
Cite this article as:
Chye Ooi Teik and G. Nordestgaard Borge, Methods to Study Postprandial Lipemia, Current Vascular Pharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157016111795495567
DOI https://dx.doi.org/10.2174/157016111795495567 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) In Vivo, Cardiac-Specific Knockdown of a Target Protein, Malic Enzyme- 1, in Rat via Adenoviral Delivery of DNA for Non-Native miRNA
Current Gene Therapy Saturation of the Human Phenome
Current Genomics Biomarkers of Subclinical Atherosclerosis and Natural Products as Complementary Alternative Medicine
Current Pharmaceutical Design Modulation of Neuro-Inflammation and Vascular Response by Oxidative Stress Following Cerebral Ischemia-Reperfusion Injury
Current Medicinal Chemistry Lipases as Modulators of Atherosclerosis in Murine Models
Current Drug Targets Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Carbohydrate Reward and Psychosis: An Explanation For Neuroleptic Induced Weight Gain and Path to Improved Mental Health?
Current Neuropharmacology Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Motility Disorders, Functional Gastrointestinal Disorders, Inflammatory Bowel Disease and Cardiac Rhythm Disturbances - Is there a Link? Review of Literature
Current Drug Targets Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Properties of Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) and its Applications in Tissue Engineering
Current Stem Cell Research & Therapy Microbial Agents, Immune Function and Atheromatosis: The Chlamydophila pneumoniae Role
Current Immunology Reviews (Discontinued) Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Molecular Structural Characteristics of Estrogen Receptor Modulators as Determinants of Estrogen Receptor Selectivity
Mini-Reviews in Medicinal Chemistry Management of Blood Pressure and Heart Rate in Patients with Acute Stroke
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued)